- Home
- ANNX vs HFRO Comparison
ANNX vs HFRO Comparison
Compare ANNX & HFRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANNX
- HFRO
- Stock Information
- Founded
- ANNX 2011
- HFRO 2000
- Country
- ANNX United States
- HFRO United States
- Employees
- ANNX N/A
- HFRO N/A
- Industry
- ANNX Biotechnology: Pharmaceutical Preparations
- HFRO Finance/Investors Services
- Sector
- ANNX Health Care
- HFRO Finance
- Exchange
- ANNX Nasdaq
- HFRO Nasdaq
- Market Cap
- ANNX 263.3M
- HFRO 287.7M
- IPO Year
- ANNX 2020
- HFRO N/A
- Fundamental
- Price
- ANNX $2.50
- HFRO $5.29
- Analyst Decision
- ANNX Strong Buy
- HFRO
- Analyst Count
- ANNX 4
- HFRO 0
- Target Price
- ANNX $12.50
- HFRO N/A
- AVG Volume (30 Days)
- ANNX 1.8M
- HFRO 179.8K
- Earning Date
- ANNX 08-11-2025
- HFRO 01-01-0001
- Dividend Yield
- ANNX N/A
- HFRO 8.87%
- EPS Growth
- ANNX N/A
- HFRO N/A
- EPS
- ANNX N/A
- HFRO N/A
- Revenue
- ANNX N/A
- HFRO N/A
- Revenue This Year
- ANNX N/A
- HFRO N/A
- Revenue Next Year
- ANNX N/A
- HFRO N/A
- P/E Ratio
- ANNX N/A
- HFRO N/A
- Revenue Growth
- ANNX N/A
- HFRO N/A
- 52 Week Low
- ANNX $1.29
- HFRO $4.24
- 52 Week High
- ANNX $7.85
- HFRO $6.45
- Technical
- Relative Strength Index (RSI)
- ANNX 53.37
- HFRO 57.95
- Support Level
- ANNX $2.50
- HFRO $5.18
- Resistance Level
- ANNX $2.97
- HFRO $5.31
- Average True Range (ATR)
- ANNX 0.27
- HFRO 0.07
- MACD
- ANNX -0.02
- HFRO -0.00
- Stochastic Oscillator
- ANNX 58.73
- HFRO 88.89
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
About HFRO Highland Opportunities and Income Fund of Beneficial Interest
Highland Opportunities and Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to Income Fund seeks growth of capital along with income. It focuses on making investments in real estate securities, including Reits, secured and unsecured fixed-rate loans and corporate bonds, mezzanine securities, structured products, convertible and preferred securities and equities (public and private), and floating rate securities.